ad image

Advanced Therapies

1 / 1
Driving Therapeutic Innovation with OMVs and EVs
OMVs and EVs

Driving Therapeutic Innovation with OMVs and EVs

Ola Tuvesson; Isa Lindgren, Ph.D.

NorthX Biologics

PAO-02-25-CL-09Mar 21, 2025
Ensuring Nuclease Free Process Consumables for Biopharma Applications
Advanced Therapies

Ensuring Nuclease Free Process Consumables for Biopharma Applications

Richard Fry

Sanisure

PAO-01-25-CL-05Jan 22, 2025
Synthetic DNA Delivers a Sustainable Future for Genetic Medicines
Sustainability

Synthetic DNA Delivers a Sustainable Future for Genetic Medicines

Touchlight

PAO-01-25-CL-04Jan 07, 2025
Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery using dbDNA
Nonviral Delivery

Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery using dbDNA

Lisa Caproni

Touchlight

PAO-12-24-CL-4Dec 16, 2024
The Groundbreaking Potential of CRISPR Gene Editing
CRISPR

The Groundbreaking Potential of CRISPR Gene Editing

Olivia Newton-John Cancer Research Institute

PAO-10-24-RTM-09Nov 05, 2024
Innovating and Collaborating to Support Biopharma Beyond the Typical CDMO
CDMO

Innovating and Collaborating to Support Biopharma Beyond the Typical CDMO

Janet Hoogstraate, Ph.D.

NorthX Biologics

PAO-10-24-CL-07Oct 07, 2024
Optimized Residual dsRNA Detection for mRNA Therapeutics
RNA

Optimized Residual dsRNA Detection for mRNA Therapeutics

Eunseo (Ency) Lee, Ph.D; Namhyun Kim; Hwanjun Yoon, Ph.D.; Sukhwan Kim; Ahyeon Hwang

Samsung Biologics

PAO-09-24-CL-07Sep 30, 2024
MegaBulb DNA: a Non-Viral ssDNA Breakthrough Revolutionizing Gene Editing
Gene Editing

MegaBulb DNA: a Non-Viral ssDNA Breakthrough Revolutionizing Gene Editing

Tom Adie, Ph.D.; Elena Stoyanova, Ph.D.

Touchlight

PAO-10-24-CL-01Sep 30, 2024
PROTACS: Upgrading Small Molecule Inhibitors
Protein Degradation

PROTACS: Upgrading Small Molecule Inhibitors

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-06-24-NI-02Jun 11, 2024
Building Multiple Platforms to Address Difficult-to-Treat Cancers
Immuno-Oncology

Building Multiple Platforms to Address Difficult-to-Treat Cancers

Derek Hennecke

Inceptor Bio

PAO-05-22-R250-09May 24, 2022
The Evolution and the Future of Pharma
Pharma's Almanac

The Evolution and the Future of Pharma

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-03-22-R250-07Mar 08, 2022
Realizing the Promise of Cell and Gene Therapy with an Advanced Manufacturing Platform
Cell and Gene Therapy

Realizing the Promise of Cell and Gene Therapy with an Advanced Manufacturing Platform

Shailesh Maingi; Mike Nicholson, Ph.D.

Inceptor Bio

PAO-01-22-R250-15Jan 31, 2022
Enabling Novel Cell Therapies by Leveraging Established Blood Stem Cell Transplant Infrastructure
Cell Therapy

Enabling Novel Cell Therapies by Leveraging Established Blood Stem Cell Transplant Infrastructure

Chris McClain

Be The Match BioTherapies

PAO-09-21-CL-04Sep 09, 2021
Realizing the Promise of RNA Therapies with Lipid Nanoparticle Delivery
mRNA Therapies

Realizing the Promise of RNA Therapies with Lipid Nanoparticle Delivery

Shiksha Mantri, Ph.D.

MilliporeSigma

PAO-06-21-CL-08Jun 16, 2021
Expanding a Comprehensive Platform to Support the Future of Cell and Gene Therapies
Cell and Gene Therapy

Expanding a Comprehensive Platform to Support the Future of Cell and Gene Therapies

David Y. H. Chang, Ph.D.

WuXi Advanced Therapies

PAO-05-21-CL-05May 27, 2021
Q: Putting aside COVID-19 vaccines and therapeutics, what do you think will be the most significant development in the industry in 2021?
COVID-19 Impacts

Q: Putting aside COVID-19 vaccines and therapeutics, what do you think will be the most significant development in the industry in 2021?

Pharma's Almanac

PAO-03-21-NI-01Mar 16, 2021
Advanced Therapies: Landscape, the Road Forward, and M&A
Cell and Gene Therapy

Advanced Therapies: Landscape, the Road Forward, and M&A

Thomas Isett

i.e. Advising

PAP-Q2-2019-CL-021May 24, 2019
1 / 1